Lab
Theranostix INC
Theranostix INC was paid $5.27M by Medicaid between Jan 2018 and Nov 2024, across 64 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 29% of everything it billed.
33Billing provider infoTHERANOSTIX INC
BELTSVILLE, MD 20705
BELTSVILLE, MD 20705
33aNPI1992812473assigned 08/23/2006
33bProvider typeClinical Medical Laboratory
28Total paid$5.27M
24GClaims152,256
24DCodes billed64
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Maryland
Rank by total paid#15 of 93
Median peer was paid$430K
This provider vs. median12×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 5,479 | $170K | |
| 2019 | 3,370 | $106K | |
| 2020 | 21,940 | $860K | |
| 2021 | 35,130 | $1.19M | |
| 2022 | 54,287 | $1.56M | |
| 2023 | 22,251 | $866K | |
| 2024incomplete | 9,799 | $517K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 29% | 22,572 | 20,073 | $1.54M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 26% | 24,468 | 14,795 | $1.39M |
| 88313 | 12% | 12,301 | 11,304 | $643K | |
| 88342 | 12% | 11,899 | 10,728 | $621K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 4.2% | 4,538 | 3,793 | $221K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 3.3% | 13,056 | 6,787 | $177K |
| 88312 | 2.7% | 4,806 | 4,289 | $144K | |
| 88112 | 1.8% | 3,970 | 3,599 | $92K | |
| 87150 | <1% | 774 | 717 | $47K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,548 | 1,435 | $42K |
| 88360 | <1% | 561 | 520 | $39K | |
| 87481 | <1% | 3,915 | 3,375 | $33K |
52 more codes
| 87556 | <1% | 3,799 | $26K | |
| 87640 | <1% | 3,896 | $23K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,854 | $22K |
| 87653 | <1% | 4,019 | $22K | |
| 88121 | <1% | 148 | $20K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,280 | $16K |
| 87563 | <1% | 3,365 | $14K | |
| 87500 | <1% | 2,065 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,410 | $10K |
| 80061 | Lipid panel | <1% | 1,637 | $10K |
| 88120 | <1% | 70 | $8K | |
| 80053 | Comprehensive metabolic panel | <1% | 1,746 | $7K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,124 | $7K |
| 88304 | <1% | 364 | $6K | |
| 81265 | <1% | 154 | $6K | |
| 82607 | <1% | 983 | $6K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,690 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,292 | $5K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 592 | $5K |
| 87529 | <1% | 354 | $5K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 590 | $4K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 130 | $4K |
| 87186 | <1% | 2,156 | $4K | |
| 81266 | <1% | 131 | $3K | |
| 87532 | <1% | 841 | $3K | |
| 82746 | <1% | 471 | $3K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 22 | $2K |
| 87631 | <1% | 379 | $2K | |
| 87496 | <1% | 390 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,226 | $2K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 406 | $2K |
| 87486 | <1% | 499 | $2K | |
| 83993 | <1% | 166 | $2K | |
| 87506 | <1% | 78 | $2K | |
| 88341 | <1% | 34 | $2K | |
| 87581 | <1% | 467 | $1K | |
| 84439 | <1% | 331 | $1K | |
| 87077 | <1% | 674 | $930.45 | |
| 82728 | <1% | 54 | $531.02 | |
| 82274 | <1% | 57 | $495.36 | |
| 82656 | <1% | 83 | $492.79 | |
| 87498 | <1% | 358 | $378.95 | |
| 81001 | <1% | 337 | $368.23 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 15 | $202.11 |
| 86803 | <1% | 16 | $146.44 | |
| 87338 | <1% | 14 | $143.80 | |
| 84153 | <1% | 13 | $98.58 | |
| 84378 | <1% | 13 | $83.34 | |
| 88142 | <1% | 13 | $68.79 | |
| 83540 | <1% | 13 | $59.63 | |
| 86592 | <1% | 16 | $39.62 | |
| 80050 | General health panel | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKOTHANDARAM, SATHISH (PRESIDENT & CEO)
| Provider | Location | Paid |
|---|---|---|
| P4 Clinical LLC | Pine Brook, NJ | $964K |
| Long Island Pathology INC | East Setauket, NY | $306K |
| Platinum Pathology, PLLC | Glen Allen, VA | $216K |
| Excel Medical Lab. INC | Edison, NJ | $150K |
| Theranostix INC | Indianapolis, IN | $8K |
| Metamark Laboratories, INC. | Augusta, GA | $569.11 |
| P4 Diagnostix LLC | Beltsville, MD | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.